These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31145389)

  • 21. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to bevacizumab: a pilot study.
    van Asten F; Klevering BJ; Hoyng CB
    Acta Ophthalmol; 2017 Aug; 95(5):e426-e427. PubMed ID: 27350361
    [No Abstract]   [Full Text] [Related]  

  • 23. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
    Mantel I; Dirani A; Zola M; Parvin P; De Massougnes S; Bergin C
    Retina; 2019 May; 39(5):906-917. PubMed ID: 29370035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
    Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study.
    Tiosano L; Segal O; Mathalone N; Pollack A; Ehrlich R; Klemperer I; Barak Y; Moroz I; Chowers I; Goldstein M
    Eye (Lond); 2017 Jun; 31(6):890-898. PubMed ID: 28211882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
    Chhablani J; Dedhia CJ; Peguda HK; Stewart M
    Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration.
    Kıyat P; Menteş J; Nalçacı S; Afrashi F; Barış M
    Turk J Ophthalmol; 2021 Jun; 51(3):161-168. PubMed ID: 34187151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION: Incidence and Characteristics.
    Bilgic A; Kodjikian L; Mathis T; Sudhalkar AA; Vasavada SA; Bhojwani DM
    Retina; 2021 Sep; 41(9):1901-1910. PubMed ID: 33411472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START).
    Korobelnik JF; Souied EH; Oubraham H; Razavi S; Mauget-Faÿsse M; Savel H; Chene G; Wolf S
    Retina; 2021 Mar; 41(3):588-594. PubMed ID: 33600134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
    Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
    Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.
    Ozturk M; Harris ML; Nguyen V; Barthelmes D; Gillies MC; Mehta H
    Clin Exp Ophthalmol; 2018 May; 46(4):407-411. PubMed ID: 29044979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register.
    Lövestam Adrian M; Vassilev ZP; Westborg I
    Acta Ophthalmol; 2019 Feb; 97(1):91-98. PubMed ID: 30238648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraocular Pharmacokinetics of Aflibercept and Vascular Endothelial Growth Factor-A.
    Celik N; Scheuerle A; Auffarth GU; Kopitz J; Dithmar S
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5574-8. PubMed ID: 26305529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration.
    Ferrone PJ; Anwar F; Naysan J; Chaudhary K; Fastenberg D; Graham K; Deramo V
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i17-21. PubMed ID: 24795335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
    Augsburger M; Sarra GM; Imesch P
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.